Evidence map›Paper›PMID 35969350›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2022

A m

Mengyuan Lei, Chenghan Luo, Jiayang Zhang, Wenjun Cao, Jian Ge, Min Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Aberrant RNA mCell death & disease · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mengyuan Lei *Physical Examination Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Chenghan Luo *Orthopedics Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. chenghanluo@zzu.edu.cn.ORCID http://orcid.org/0000-0002-0815-8000
Jiayang Zhang *Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Wenjun CaoNeonatal Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Jian GeNeonatal Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Min ZhaoMedical record department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
First Affiliated Hospital of Zhengzhou University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs the most abundant modification in mRNA, the N

methodsWe identified m

resultsA m

conclusionsOur results suggest that the m

Indexed as

Adenocarcinoma of LungLung NeoplasmsHumansImmunotherapyMethyltransferasesRNARNA, MessengerTumor MicroenvironmentMethyltransferasesRNARNA, MessengerImmune geneImmune microenvironmentImmunotherapyLung adenocarcinomaN6-methyladenosine

Identifiers

PMID35969350
PMCPMC12978116
OpenAlexW4291552401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.